Form 8-K - Current report:
SEC Accession No. 0001558370-23-001826
Filing Date
2023-02-23
Accepted
2023-02-23 07:15:21
Documents
14
Period of Report
2023-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20230223x8k.htm   iXBRL 8-K 46173
2 EX-99.1 acrs-20230223xex99d1.htm EX-99.1 187355
3 GRAPHIC acrs-20230223xex99d1001.jpg GRAPHIC 13042
  Complete submission text file 0001558370-23-001826.txt   385373

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20230223.xsd EX-101.SCH 3054
5 EX-101.LAB acrs-20230223_lab.xml EX-101.LAB 16012
6 EX-101.PRE acrs-20230223_pre.xml EX-101.PRE 10319
8 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230223x8k_htm.xml XML 4842
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 23655918
SIC: 2834 Pharmaceutical Preparations